Although the pathway involving APP/Aβ/tau represents the dominant mechanism of AD pathogenesis, the failure of many drug development efforts at the late stage trial raises the possibility that other non-amyloid AD mechanisms or alternative pathways should be explored in the development of therapeutics for AD [2]. Here, MAPT is linked to Alzheimer disease.